Who is sponsoring NCT05015556?

NCT05015556 is sponsored by Goorens Chul Ki.

What drugs are being tested in NCT05015556?

Interventions in NCT05015556: Minimal invasive volar plating.

What condition does NCT05015556 study?

NCT05015556 studies Radius Fracture Distal.

Is NCT05015556 still recruiting?

NCT05015556 is currently status unknown. Last updated 5 October 2022.

Last reviewed 2022-10-05 · How we verify

NCT05015556

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minimal Invasive Volar Plating Versus Cast Immobilization for Treatment of Stable Non-displaced Distal Radial Fractures.

Status unknown NA Last updated 5 October 2022

What this trial tests

NA trial testing Minimal invasive volar plating in Radius Fracture Distal in 90 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Goorens Chul Ki
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	90
Start date	1 September 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Belgium

Drugs / interventions tested

Minimal invasive volar plating

Conditions studied

Radius Fracture Distal — all drugs for Radius Fracture Distal →

Sponsor

Goorens Chul Ki

Who can join

Adults 16 to 65, any sex, with Radius Fracture Distal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nondisplaced distal radial fractures are nowadays treated by plaster cast immobilization. In this study, the investigators challenge this classical standard treatment with a surgical solution: minimal invasive volar plating with pronatus quadratus sparing approach. Potential benefits of this surgical treatment are higher cost effectiveness, economical benefit, earlier recuperation of professional and recreational activities, earlier functional recuperation by faster clinical recovery (range of motion, grip strength) and decreased risk of secondary fracture displacement. Potential drawbacks are surgical risks and complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05015556 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Goorens Chul Ki
Last refreshed: 5 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05015556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing